Nuclear medicine and biology最新文献

{"title":"Development of a novel xCT transporter imaging using a radiopharmaceutical with inhibitor-type compounds","authors":"Kakeru Sato ,&nbsp;Jundai Yamagata ,&nbsp;Yuka Hirayama ,&nbsp;Yuna Hamada ,&nbsp;Jianwei Yao ,&nbsp;Asuka Mizutani ,&nbsp;Masato Kobayashi ,&nbsp;Ryuichi Nishii ,&nbsp;Naoto Shikano ,&nbsp;Munetaka Kunishima ,&nbsp;Keiichi Kawai","doi":"10.1016/j.nucmedbio.2026.109625","DOIUrl":"10.1016/j.nucmedbio.2026.109625","url":null,"abstract":"<div><h3>Background</h3><div>The cystine/glutamate antiporter xCT has attracted attention due to its role in maintaining redox homeostasis. Noninvasive techniques for visualizing xCT expression in tumors provide valuable diagnostic information for evaluating tumor biology. Therefore, we developed and evaluated a novel SPECT radiopharmaceutical to visualize xCT expression in cancer cells based on inhibitors.</div></div><div><h3>Methods</h3><div>We designed and synthesized a radioiodinated SSZ derivative ([¹²⁵I]I-SSZd), based on the structure of sulfasalazine (SSZ)—an xCT inhibitor. We radioiodinated 4-hydroxy-<em>L</em>-phenylglycine (L-HPG) and 4-hydroxy-<em>D</em>-phenylglycine (D-HPG) to synthesize [¹²⁵I]I-L-HPG and [¹²⁵I]I-D-HPG, respectively. The affinities of [¹²⁵I]I-SSZd, [¹²⁵I]I-L-HPG, and [¹²⁵I]I-D-HPG to xCT were evaluated using SSZ and cystine inhibition assays in two human-derived colon cancer cell lines (LS180 and DLD-1). xCT expression was quantified using real-time polymerase chain reaction. <em>In vivo</em>, the biodistribution of [¹²⁵I]I-L-HPG was examined in tumor-bearing mice. Stability analysis was performed in mice liver and kidney homogenates.</div></div><div><h3>Results</h3><div>[¹²⁵I]I-L-HPG showed high affinity for xCT. [¹²⁵I]I-D-HPG exhibited some affinity for xCT. xCT was not involved in [¹²⁵I]I-SSZd accumulation. The gene expression levels of xCT were higher in LS180 than in DLD-1 cells. [¹²⁵I]I-L-HPG and [¹²⁵I]I-D-HPG showed high accumulation in LS180 cells. [¹²⁵I]I-L-HPG showed higher accumulation than [¹²⁵I]I-D-HPG in both cell lines. In the kidneys, [¹²⁵I]I-L-HPG accumulation decreased over time. In the thyroid, [¹²⁵I]I-L-HPG accumulation increased over time; however, deiodination did not occur in mice. Tumor-to-muscle ratio was &gt;2.0 at almost all timepoints for both types of tumor-bearing mice, and the maximum tumor-to-large intestine ratio reached 4.0 in LS180 tumors with high xCT expression.</div></div><div><h3>Conclusion</h3><div>In tumors, [¹²⁵I]I-L-HPG shows promise as a radiopharmaceutical by exhibiting high affinity for xCT.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"156 ","pages":"Article 109625"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147802222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative biological evaluation of [18F]fluciclovine, [18F]FBPA-Fr, and [18F]FET for boron neutron capture therapy: Preclinical validation and clinical feasibility","authors":"Ting-Yu Chang ,&nbsp;Ko-Han Lin ,&nbsp;Tzu-Yu Lee ,&nbsp;Yi-Ting Tsai ,&nbsp;Yi-Wei Chen ,&nbsp;Cheng-Lin Wu ,&nbsp;Chun-Yi Wu","doi":"10.1016/j.nucmedbio.2026.109636","DOIUrl":"10.1016/j.nucmedbio.2026.109636","url":null,"abstract":"<div><h3>Purpose</h3><div>The PET tracer 4‑borono-2-[¹⁸F]-fluoro-phenylalanine fructose ([¹⁸F]FBPA-Fr) is commonly used to estimate the biodistribution of L-4-dihydroxy-borylphenylalanine fructose (BPA-Fr). However, its limited regulatory approval has prompted the exploration of alternative imaging agents. In this study, we evaluated the feasibility of [¹⁸F]fluciclovine and [¹⁸F]fluoroethyl-tyrosine ([¹⁸F]FET) PET for pre-BNCT assessment, with direct comparison to [¹⁸F]FBPA-Fr.</div></div><div><h3>Methods</h3><div>In vitro cellular uptake studies were performed using two different cancer cell lines. In vivo microPET/MR imaging and biodistribution analyses were conducted in mice bearing wild-type and L-type amino acid transporter 1 (LAT1)-knockdown GBM8401 tumors. The therapeutic efficacy of BPA-Fr-based BNCT was evaluated in tumor-bearing mice. In addition, a pilot clinical study compared [¹⁸F]fluciclovine and [¹⁸F]FBPA-Fr PET imaging in participants with brain and head-and-neck tumors.</div></div><div><h3>Results</h3><div>[¹⁸F]FBPA-Fr uptake was strongly dependent on LAT1 expression, decreasing by approximately 60 % in LAT1-knockdown cells, whereas [¹⁸F]fluciclovine uptake was reduced by only ~10 %. In vivo, [¹⁸F]FET showed the highest absolute tumor uptake but the lowest tumor-to-normal brain (T/N) ratio due to high background activity. Mice with high [¹⁸F]fluciclovine tumor uptake exhibited significantly prolonged survival following BNCT (15–17 days) compared with controls (~10 days). Clinically, [¹⁸F]fluciclovine and [¹⁸F]FBPA-Fr showed comparable T/N ratios in patients with pontine glioma and maxillary sinus carcinoma. Moreover, [¹⁸F]fluciclovine PET visualized metabolic changes after BNCT, which were consistent with subsequent disease progression.</div></div><div><h3>Conclusion</h3><div>Although [¹⁸F]FBPA-Fr remains the most LAT1-specific tracer, [¹⁸F]fluciclovine provides comparable tumor-to-normal tissue contrast and reliable imaging performance, supporting its role as a clinically feasible alternative for pre-BNCT patient selection and treatment response assessment.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"156 ","pages":"Article 109636"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147995463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outside Back Cover - Graphical abstract TOC/TOC in double column/Cover image legend if applicable, Bar code, Abstracting and Indexing information","authors":"","doi":"10.1016/S0969-8051(26)00048-X","DOIUrl":"10.1016/S0969-8051(26)00048-X","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"156 ","pages":"Article 109649"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of angiostatin based radiopharmaceutical as a sensitive tool for detection of ATP synthase during acute vascular damage","authors":"Ankon Das ,&nbsp;Tikum Florence ,&nbsp;Carolina Rego Rodrigues ,&nbsp;Barbara Ambros ,&nbsp;Jaswant Singh ,&nbsp;Humphrey Fonge ,&nbsp;Gurpreet Kaur Aulakh","doi":"10.1016/j.nucmedbio.2026.109633","DOIUrl":"10.1016/j.nucmedbio.2026.109633","url":null,"abstract":"<div><h3>Background</h3><div>Angiostatin (ANG) is an endogenously cleaved protein of the plasminogen-plasmin conversion pathway which is activated during tumor angiogenesis and oxidative stress. One of the hallmarks of sub-clinical oxidative stress are persistent aggregation of platelets and neutrophils (and other immune cells) leading to endothelial activation. The goal of the study was to develop and test the specificity of a highly glycosylated form of ANG, derived from neutrophil elastase, as an in vivo radiopharmaceutical marker of oxidative stress and to monitor the progression of vascular and platelet activation.</div></div><div><h3>Methods</h3><div>Sequential PET imaging of radiolabeled ANG ([⁸⁹Zr]Zr-ANG) in a combined ozone and LPS induced murine model of oxidative stress (<em>n</em> = 8 per group) was followed by whole-body, fractionated blood, aortic ring and platelet biodistribution studies. In vitro, platelets were exposed to H₂O₂ and/or LPS to induce oxidative stress.</div></div><div><h3>Results</h3><div>Compared with sham mice, the uptake of [⁸⁹Zr]Zr-ANG in the exposed lungs was 4.8 to 8.5-fold (male mice) and 4.2 to 11.6-fold (female mice) higher over 72 h after ozone and LPS exposure (<em>p</em> &lt; 0.0001). Ex vivo biodistribution and microPET/CT imaging revealed accumulation of [⁸⁹Zr]Zr-ANG in platelets and multiple organs including lungs highlighting vascular inflammation and platelet activation in response to ozone and LPS. Uptake of ANG in aorta and platelets was confirmed by injecting ozone and LPS exposed mice with fluorescent angiostatin. Lastly, platelets subjected to oxidative stress preferentially bind ANG compared to untreated platelets and split them into ATP-rich ultra-small (0.7–10 nm) vesicles and large (1–10 μm) micro-particles. This binding is dependent upon ATP inhibitory factor, IF1's displacement to bind with ATP synthase subunit β (ATPβ).</div></div><div><h3>Conclusions</h3><div>[⁸⁹Zr]Zr-ANG is a stable, ATP synthase directed endothelial cell and platelet-specific imaging tool for detection of acute murine oxidative stress-induced lung as well as systemic inflammation. Thus, the current study provides evidence towards potential applications of [⁸⁹Zr]Zr-ANG in understanding the fate of platelets in chronic disease models.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"156 ","pages":"Article 109633"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147875200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical characterization of a novel FAP-targeted PET tracer, [68Ga]Ga-CB6NT-FAPI","authors":"Hye Yeon Seo ,&nbsp;Hwa Sil Kim ,&nbsp;Ran Ji Yoo ,&nbsp;Kwon Kim ,&nbsp;Jae Min Jeong ,&nbsp;Yun-Sang Lee","doi":"10.1016/j.nucmedbio.2026.109632","DOIUrl":"10.1016/j.nucmedbio.2026.109632","url":null,"abstract":"<div><div>Fibroblast activation protein (FAP) is an established target for molecular imaging of the tumor stroma. In this study, we report the development and preclinical evaluation of a novel FAP-targeted positron emission tomography (PET) tracer, [⁶⁸Ga]Ga-CB6NT-FAPI.</div><div>[⁶⁸Ga]Ga-CB6NT-FAPI was efficiently radiolabeled under mild conditions (room temperature, 10 min), yielding high radiochemical purity (&gt;99.9%) and demonstrating excellent <em>in vitro</em> stability. <em>In vitro</em> studies showed significantly higher uptake in FAP-positive cells than in FAP-negative cells, which was reduced by excess unlabeled ligand, confirming FAP-specific binding.</div><div><em>In vivo</em> PET/MR imaging in a U87MG xenograft model demonstrated clear tumor uptake with favorable contrast. Blocking studies resulted in a marked reduction in tumor signal, and <em>ex vivo</em> biodistribution confirmed specific tumor accumulation with an approximately 99.9% reduction under blocking conditions.</div><div>The tracer exhibited partial hepatobiliary involvement in addition to renal clearance. These findings indicate that CB6NT-FAPI represents a pharmacokinetically differentiated FAPI tracer that expands the diversity of FAP-targeted PET imaging by providing an alternative balance between renal and hepatobiliary clearance.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"156 ","pages":"Article 109632"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147931845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NMB innovators Series Professor Olof Solin: Bridging the gap between the targetry and clinical diagnostics","authors":"Anna K. Kirjavainen ,&nbsp;Sarita Forsback ,&nbsp;Anu J. Airaksinen","doi":"10.1016/j.nucmedbio.2026.109640","DOIUrl":"10.1016/j.nucmedbio.2026.109640","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"156 ","pages":"Article 109640"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148055674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous association of different forms of non-conjugated astatine-211 to serum albumin","authors":"Emma Aneheim ,&nbsp;Sture Lindegren ,&nbsp;Holger Jensen ,&nbsp;Tom Bäck","doi":"10.1016/j.nucmedbio.2026.109608","DOIUrl":"10.1016/j.nucmedbio.2026.109608","url":null,"abstract":"<div><h3>Aim/introduction</h3><div>Astatine-211 is one of the alpha-particle emitting nuclides investigated for use within Targeted Alpha Therapy (TAT) of disseminated cancer. In previous studies, a difference in blood clearance has been observed when comparing astatinated compounds with their iodinated counterparts. This has been explained by a potentially prolonged retention in the blood by present free astatine. This study examined the spontaneous binding of non-conjugated astatine to albumin under physiological conditions in vitro and compared it to that of iodine. Additionally, the in vivo blood circulation patterns of free astatine were assessed and contrasted with those of iodine.</div></div><div><h3>Materials and methods</h3><div>Astatine solutions were formulated following dry distillation and evaporation to dryness of astatine solvated in CHCl₃. In vitro evaluation of astatine and iodine association to albumin was mainly performed using size exclusion chromatography applying both disposable columns (PD10 and NAP10) as well as an FPLC system (ÄKTA) with online UV detection and activity fraction collection. Also methanol precipitation and radio-TLC methods were used for analysis. In vivo evaluation was performed using furry BALB/C mice (3/group) with both i.v. and i.p. injection of astatine, followed by sequential blood sampling from the tail vein and biodistribution.</div></div><div><h3>Results</h3><div>Oxidized and unmodified forms of free astatine display a significantly higher and more rapid association to albumin in vitro compared to reduced forms, with &gt;97% compared to &lt;25% associated after 10 min. Both the corresponding oxidized and reduced forms of iodine display a very low and slow association to albumin with &lt;5% associated after 40 min. Oxidized, unmodified and reduced astatine show very similar blood profiles over time as well as a similar uptake in biodistribution after 20–22 h following i.p. injection. Upon i.v. injection a larger difference in blood profiles between the species could be observed, which in turn was different compared to the curve obtained after i.p. injection. In addition, an unexpected uptake of astatide in stomach was found. In all cases the blood profile and biodistribution of astatine was significantly different compared to iodine, which displayed a greater and more rapid blood clearance and specific accumulation in thyroid.</div></div><div><h3>Conclusion</h3><div>Different forms of unbound astatine differ in their association to albumin. However, all investigated forms of free astatine associates to albumin to a much higher degree than iodine. This behavior could explain the prolonged blood circulation of free astatine compared to iodine.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"154 ","pages":"Article 109608"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Substitution matters: Comparison of four N,1,4-tri(methoxy-2-hydroxybenzyl)-DAZA ligands as potential PET/CT liver imaging agents","authors":"Anne Zenner ,&nbsp;Thomas Winkens ,&nbsp;Marta Pomraenke ,&nbsp;Steffen Wiegand ,&nbsp;Martin Freesmeyer ,&nbsp;Friederike Hüttner ,&nbsp;Wolfgang Weigand ,&nbsp;Birgit Weber ,&nbsp;Julia Greiser","doi":"10.1016/j.nucmedbio.2026.109604","DOIUrl":"10.1016/j.nucmedbio.2026.109604","url":null,"abstract":"<div><div>Four regioisomers of [⁶⁸Ga]Ga-TMoS-DAZA, a PET/CT radio tracer for liver function imaging, were studied as candidates of potentially improved hepatobiliary biokinetics. Liver uptake and biliary clearance behavior were compared using an in ovo model based on ostrich eggs for PET/CT imaging and ex vivo biodistribution analysis. The tracer lipophilicity was evaluated via logD determination. The experiments showed remarkable differences between the four tracers concerning their maximum liver uptake, percentage of tracer cleared via the biliary tract and their respective logD values.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"154 ","pages":"Article 109604"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of an automated one-step radiolabeling procedure for a PSMA-targeted radiotherapeutic for prostate cancer","authors":"Meltem Ocak ,&nbsp;Kanishka Sikligar ,&nbsp;Michael Pun ,&nbsp;Khanh-Van Ho ,&nbsp;Xiaoxi Ling ,&nbsp;Valerie N. Carroll ,&nbsp;Jaime Simón ,&nbsp;Melody D. Fulton ,&nbsp;Hunter N. Bomba ,&nbsp;Clifford E. Berkman ,&nbsp;Beatrice C. Langton-Webster ,&nbsp;Carolyn J. Anderson","doi":"10.1016/j.nucmedbio.2026.109607","DOIUrl":"10.1016/j.nucmedbio.2026.109607","url":null,"abstract":"<div><h3>Background</h3><div>CTT1403 (¹⁷⁷Lu-CTT2001), an irreversible phosphoramidate PSMA inhibitor developed by Cancer Targeted Technology, was initially synthesized using a two-step radiolabeling method and has previously been evaluated in first-in-human studies. This two-step approach protected the phosphoramidate pharmacophore—containing a temperature- and pH-labile P<img>N bond—from the harsh conditions required for lutetium-177 (¹⁷⁷Lu) chelation. Although the final chemical structure of CTT1403 is identical regardless of the radiolabeling route, it was not clear that CTT2001 could tolerate one-step labeling conditions while preserving PSMA-binding integrity. Therefore, the aim of the study was to develop, optimize, and automate a one-step radiolabeling method for CTT1403 and to confirm that the resulting product is biologically equivalent and exhibits comparable in vitro and in vivo behavior to CTT1403 produced by the original two-step process.</div></div><div><h3>Methods</h3><div>CTT2001 was synthesized and radiolabeled with ¹⁷⁷Lu using an optimized one-step procedure that was subsequently automated on a Trasis AllinOne synthesizer. Radiochemical purity, stability, cellular uptake/internalization, and biodistribution in PC3-PIP tumor-bearing mice were evaluated.</div></div><div><h3>Results</h3><div>CTT1403 synthesized via the one-step method demonstrated cellular uptake and internalization in PC3-PIP cells, as well as in vivo biodistribution in PC3-PIP tumor–bearing mice, that were comparable to those of the two-step–labeled product. The one-step procedure was successfully automated on the Trasis All-in-One synthesizer, producing CTT1403 with a radiochemical yield of 86.5 ± 4.27% (<em>n</em> = 3), a molar activity of 30.3 ± 1.11 MBq/nmol, and a radiochemical purity of 97.6 ± 0.80% (n = 3) in a total synthesis time of 38 min. The final product remained stable for at least 24 h at −4 °C and −20 °C.</div></div><div><h3>Conclusions</h3><div>The one-step radiolabeling method yields CTT1403 that is biologically equivalent to the two-step product and can be reliably produced using fully automated synthesis. This streamlined, efficient, and reproducible approach supports routine clinical manufacturing of CTT1403.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"154 ","pages":"Article 109607"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146093499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NMB Innovators Series Professor Dae Yoon Chi, Ph.D.: Understanding of 18F-chemistry and its applications toward drug developments used in diagnosis and therapeutics","authors":"Hee Seup Kil ,&nbsp;Byung Chul Lee ,&nbsp;Dong Wook Kim ,&nbsp;Kyo Chul Lee","doi":"10.1016/j.nucmedbio.2026.109624","DOIUrl":"10.1016/j.nucmedbio.2026.109624","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"154 ","pages":"Article 109624"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147739898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}